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Abstract
Background: Hawthorn extract has been used for cardiovascular diseases for centuries. Recent trials have
demonstrated its efficacy for the treatment of heart failure, and the results of several small trials suggest it may
lower blood pressure. However, there is little published evidence to guide its dosing. The blood pressure lowering
effect of hawthorn has been linked to nitric oxide-mediated vasodilation. The aim of this study was to investigate
the relationship between hawthorn extract dose and brachial artery flow mediated dilation (FMD), an indirect
measure of nitric oxide release.
Methods: We used a four-period cross-over design to evaluate brachial artery FMD in response to placebo or
hawthorn extract (standardized to 50 mg oligomeric procyanidin per 250 mg extract). Randomly sequenced doses
of hawthorn extract (1000 mg, 1500 mg, and 2500 mg) and placebo were assigned to each participant. Doses
were taken twice daily for 3 1/2 days followed by FMD and a 4-day washout before proceeding to the next dosing
period.
Results: Twenty-one prehypertensive or mildly hypertensive adults completed the study. There was no evidence of
a dose-response effect for our main outcome (FMD percent) or any of our secondary outcomes (absolute change
in brachial artery diameter and blood pressure). Most participants indicated that if given evidence that hawthorn
could lower their blood pressure, they would be likely to use it either in conjunction with or instead of lifestyle
modification or anti-hypertensive medications.
Conclusion: We found no evidence of a dose-response effect of hawthorn extract on FMD. If hawthorn has a
blood pressure lowering effect, it is likely to be mediated via an NO-independent mechanism.
Trial Registration: This trial has been registered with ClinicalTrials.gov, a service of the U.S. National Institutes of
Health: NCT01331486.
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Background
Hawthorn (Crataegus spp.) is a thorny shrub that grows
commonly in northern temperate regions around the
world. Typically the leaf and flower, berry, or a combi-
nation of all three are consumed as a powder, tea, or
liquid extract. Its therapeutic use is reported as early as
the 1st century BCE, and references to its use in cardio-
vascular diseases date to the 1600’s [1].
The chemical constituents considered to be the pri-
mary bioactive components of hawthorn are the flavo-
noids and oligomeric procyanidins (OPCs) [2].
Hawthorn extracts have been shown to enhance release
of nitric oxide (NO) from vascular endothelium causing
vasodilation, which appears to be associated with the
OPC-rich fraction of hawthorn extract [3-5].
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While traditional indications for use of hawthorn
include asthma, diabetes, and neurasthenia [6], the most
substantial evidence for its benefit resides in treatment
of mild to moderate heart failure (HF) [7,8]. As an
adjunct to conventional treatment in patients with HF
(New York Heart Association classes I - III), hawthorn
extract may provide additional benefit in symptom con-
trol (eg. fatigue, shortness of breath) and physiologic
outcomes (eg. maximal work load tolerance, exercise
tolerance, pressure-heart rate product) [8]. Several small
clinical trials with hawthorn have demonstrated modest
blood pressure reduction [9-11], and a few preclinical
studies have shown reductions in total cholesterol, low-
density lipoprotein, and ApoB synthesis [12-16]. How-
ever, there are no published evaluations of human dose-
response to hawthorn to guide its dosing. We sought to
evaluate the dose-response effect of a hawthorn extract
standardized to OPC concentration on flow-mediated
dilation of the brachial artery (FMD), an indirect mea-
sure of NO release [17].
Methods
Participants
English-speaking adults aged 18 years and older with
recent average ambulatory systolic blood pressure (BP)
between 120-155 mmHg and diastolic BP between 80-
95 mmHg were eligible for enrollment. People using any
antihypertensive medications or tobacco products, as
well as those with a prior diagnosis of diabetes mellitus,
coronary artery disease, severe aortic stenosis, idiopathic
hypertrophic subaortic stenosis, or upper extremity vas-
cular obstruction were excluded. Pregnant or breast-
feeding women, and women using estrogen-containing
birth control methods, were also excluded. All partici-
pants were instructed to forego the use of dietary sup-
plements such as vitamins C and E, fish oil, niacin,
arginine, and over-the-counter decongestants and non-
steroidal anti-inflammatory agents for the duration of
the study. Participants were asked to refrain from alco-
hol, vigorous exercise, and use of phosphodiesterase
inhibitors prior to study visits. Participants experiencing
any respiratory or viral illness associated with fever, as
well as any acute inflammatory conditions, were sus-
pended from involvement in the study until the acute
illness had resolved. The Institutional Review Board at
the University of North Carolina approved the research
protocol, and all study participants gave written consent
prior to participation in the study.
Study design
We used a randomized, placebo-controlled, double-
blind, four-period crossover design. Each participant had
brachial artery FMD measured at baseline and after
each dosing period. Capsules containing 250 mg of
hawthorn standardized extract (HSE) and a sufficient
number of matching placebo capsules were combined to
create four dosage levels: placebo, 1000 mg, 1500 mg,
and 2500 mg. We chose two doses (ie. 1000 mg [200
mg OPC], 1500 mg [300 mg OPC]) to approximate the
previously reported doses from heart failure trials (ie.
900 mg [168 mg OPC], 1800 mg [337 mg OPC])
[18-20] and a third dose (2500 mg [500 mg OPC])
above those previously tested.
Capsules were prepackaged into single-dose cups each
containing five capsules that were taken twice daily (e.g.,
at 1500 mg, each dose cup contained 3 HSE and 2 pla-
cebo capsules). Within each period, doses were taken
for three consecutive days followed by a final dose on
the morning of the FMD measurement for a total of
seven consecutive doses. There was a minimum 3 1/2
day washout period between dosage levels. The washout
period was timed to be greater than 5 half-lives of the
hawthorn anthocyanidin epicatechin (t1/2 = 80 min)
[21]. Four random dose sequences were created using a
Williams design [22] and participants were randomly
assigned to sequence following a schedule generated by
an independent statistician; allocation concealment was
accomplished using consecutively numbered sealed opa-
que envelopes. The study pharmacist opened envelopes
in sequential order and dispensed the appropriate dose
cups; all other study personnel were blinded until all
participants completed follow-up.
HSE (Hawthorn Supreme Liquid Phyto-Caps) and
matching placebo were obtained from Gaia Herbs, Inc.,
Brevard, NC. The extract was produced from a single,
certified organic study lot grown at the Gaia Herb Farm
and was processed using a standard protocol. Extraction
solvents included grain alcohol and water. Approxi-
mately 1000 mg of whole leaf and flower was used to
produce a single 250 mg capsule standardized to 50 mg
oligomeric procyanidins, which was verified using ultra-
violet-visible spectroscopy. Placebo caps were matched
for color and liquid viscosity.
Procedures
FMD was measured using a 12.5 MHz imaging probe
interfaced with an ATL HDI 5000 ultrasound machine.
A single experienced technician performed all FMD
measurements under standard conditions (i.e., partici-
pants fasted overnight, measurements were taken in the
morning) [23].
Participants were asked to lie supine on a stretcher in
a quiet private room, and a pneumatic tourniquet was
placed around the right lower arm distal to the brachial
artery. Gated baseline images of the brachial artery and
Doppler flow profiles were acquired after 15 minutes of
supine rest. The pneumatic cuff was then inflated to a
pressure of 200 mm Hg for 5 minutes and increased
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flow (i.e., hyperemia) induced by sudden cuff deflation.
A second Doppler scan was performed immediately fol-
lowing deflation, with imaging of the brachial artery for
90 seconds. Digital images of the artery were stored for
subsequent off-line quantification.
Doppler measurements of brachial arterial flow during
imaging at baseline and during hyperemia were quanti-
fied by the HDI 500 ATL ultrasound machine. The Hi-
Q trace tracked the flow curves and quantified the velo-
city-time integral (VTI) and peak systolic velocity under
each condition.
Outcome measures
Brachial arterial diameter (BAD) was measured from the
lumen-intimal interfaces of the proximal and distal
arterial walls using customized software (Brachial Tools,
Medical Imaging Applications, LLC). Data from at least
three consecutive end-diastolic frames were averaged for
each resting baseline measurement (R) and from at least
three frames at maximum dilation during reactive
hyperemia (H). Change in brachial artery diameter
(ΔBAD) and FMD %, our primary outcome, were calcu-
lated as:
BAD = H− R; FMD% = ((H− R) /R)× 100.
Blood pressure (BP) was measured by trained nursing
staff shortly after arrival to the study center. Measure-
ments were performed according to recommended tim-
ing and positioning and using the appropriate BP cuff
size by a validated automated office-type oscillometric
device [24]. Three measurements were taken and aver-
aged to determine the participant’s office BP measure-
ment for the visit. Ambulatory blood pressure
measurements used for enrollment into the study were
recorded using an Oscar 2 ambulatory BP monitor pro-
grammed to record blood pressure at 30-minute inter-
vals from 6 am to 11 pm and at hourly intervals during
the remainder of the day.
Side Effects, Adherence, and Acceptability
Side effects and adverse events were evaluated at each
weekly follow-up visit using a symptom checklist that
was administered by the study coordinator. Symptom
severity was self-graded as mild, moderate, or severe,
and further details were elicited in free form.
Adherence to the dosing regimen was measured using
participant self-report. Participants were asked to return
any unused doses at their next study visit.
To evaluate how participants thought they might use
hawthorn if it were proven to be effective for reducing
blood pressure, we asked four questions: (1) how likely
would you be to take hawthorn instead of lifestyle modi-
fication?; (2) how likely would you be to take hawthorn
in conjunction with lifestyle modification?; (3) how likely
would you be to take hawthorn instead of a prescription
antihypertensive medication?; and (4) how likely would
you be to take hawthorn in conjunction with a prescrip-
tion antihypertensive medication? Answers were
recorded on a 5-point likert scale from ‘very likely’ to
‘very unlikely’ with ‘unsure’ at the center of the scale.
Analysis
Our primary outcome was FMD %. We tested the dose-
response effect using a modified linear contrast [25] in a
mixed effects linear regression model that included ran-
dom subject effects. The model included fixed effects
for dose, period, resting BAD within each period, and
baseline FMD %. We first assessed the potential for
carry-over effects by including dummy indicators for
dose used in the prior period (all indicators were zero
for the first period and for periods following placebo)
and conducting a 3 degree of freedom test at the 0.05
level. If non-significant, the carry-over indicators were
removed, and the modified linear contrast was tested at
the 0.05 level. If a significant dose-response effect was
observed, the pre-specified plan was pairwise testing of
each dose, in descending order, versus placebo until a
non-significant comparison was observed. Similar meth-
ods were used to assess dose-response effects on ΔBAD,
resting BAD, systolic and diastolic BP, and hyperemic
VTI. Given published information on the variance and
covariance of repeated FMD measurements and assum-
ing that a 2500 mg dose would lead to a 1% increase in
mean FMD levels, we calculated that obtaining complete
data on at least 20 participants would provide at least
80% power to detect a dose-response relationship even
if there were no effects at the lower doses [26]. All ana-
lyses were conducted in SAS, Version 9.2 (SAS Institute,
Cary, NC).
Results
We enrolled 22 participants with baseline systolic/dia-
stolic ambulatory blood pressure (ABP) between 120-
155/80-95 mm Hg from the University of North Caro-
lina at Chapel Hill catchment area between July 2010
and May 2011 (Figure 1). Twenty-one participants fully
completed the study and were included in the analyses.
Participation was halted for one subject due to hearing
loss. The mean age of participants was 51 years (range
35 - 78 years), and the mean (SD) systolic ABP was
137.6 (7.7) mm Hg and mean (SD) diastolic ABP was
81.8 (6.3) mm Hg (Table 1).
Flow-mediated dilation, brachial artery diameter, velocity-
time integral, and blood pressure
No evidence of carry-over effects for any outcome (p ≥
0.23 for all models) was observed. There was no
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evidence of a dose-response effect for our primary out-
come, FMD % (p = 0.59) (Table 2). Mean change in bra-
chial artery diameter (BAD) ranged from 0.14 mm - 0.18
mm, with no evidence of a dose-response effect (p =
0.54). The mean (SD) peak systolic velocity (cm/s) dur-
ing hyperemia was 155.3 (22.8), with minimum and
maximum velocities of 106 and 224, respectively. There
was also no evidence of a dose-response effect for rest-
ing BAD (p = 0.74) or mean resting BAD by study per-
iod (p = 0.50, data not shown). The mean (SD)
hyperemic VTI was 85.7 cm (19.9) with a range of 46.0
- 135.0 cm. Among the four groups, the mean (SD)
ranges of systolic and diastolic BP were 129.4 (8.1) -
132.0 (10.0) mm Hg and 81.8 (7.8) - 83.0 (9.1) mm Hg,
respectively, with no evidence of dose-response effects
(p = 0.33 and 0.72, respectively).
To explore the possibility that participants with higher
and lower baseline blood pressure may respond differ-
ently to HSE, we added to the primary model interac-
tions between doses of HSE and an indicator for
baseline systolic ABP either above or below the median
(129 mm Hg). We found no evidence of an interaction
(p = 0.16).
Side effects
Side effects were uncommon and the rates of events for
placebo versus HSE were typically similar. The most
common side effects were mild nausea (9.5% vs. 7.9%,
placebo vs. HSE), mild to moderate headache (14.3% vs.
15.9%), and mild palpitations (4.7% vs. 7.9%). Dizziness
occurred in only a single participant taking placebo.
One participant reported a fall (2500 mg dose) while
climbing an icy staircase, and one participant reported
partial hearing loss (during the 1000 mg dose period)
but had prior instances of idiopathic hearing loss.
Adherence, blinding, and acceptability
Overall, 78 of the 84 dose sheets (93%) were returned,
all of which indicated that doses had been taken twice a
day as directed. When the dose sheet was forgotten, we
asked participants if they had taken their pills as direc-
ted, and all participants responded affirmatively. One
participant reported taking two doses on the same
morning instead of split AM and PM. One unused dose
cup was returned by a single participant.
To assess blinding, we asked participants to guess in
which dosing period they had received placebo pills. Ele-
ven participants guessed incorrectly, one guessed cor-
rectly, and nine did not guess (we would have expected
25% to guess correctly by chance).
Most participants answered that they were likely or
very likely to use hawthorn with or instead of either life-
style modification (91% and 67%, respectively) or pre-
scription medication (57% and 86%, respectively) if
given proof that hawthorn could lower blood pressure
(Table 3).
Discussion
Hawthorn and some of its individual constituents (e.g.,
oligomeric procyanidins [OPC], flavonoids) have been
 Assessed for eligibility 
(n = 23) 
Randomized (n=22) 
Excluded 
? Did not meet inclusion criteria (n=1) 
Allocated to (n=6): 
1. Placebo 
2. 1000 mg 
3. 2500 mg 
4. 1500 mg 
Allocated to (n= 6): 
1. 1000 mg 
2. 1500 mg 
3. Placebo 
4. 2500 mg 
Allocated to (n=6): 
1. 1500 mg 
2. 2500 mg 
3. 1000 mg 
4. Placebo 
Allocated to (n= 4): 
1. 2500 mg 
2. Placebo 
3. 1500 mg 
4. 1000 mg 
Discontinued (n=1) 
? Hearing loss 
Discontinued (n=0) Discontinued (n=0) Discontinued (n=0) 
Analyzed (n=6) Analyzed (n=5) Analyzed (n=6) Analyzed (n=4) 
Figure 1 Study participant flow chart. Four random dose
sequences were created, and each individual dose was considered
a dosing period. Participants were randomly assigned to a single
sequence.
Table 1 Baseline Characteristics (N = 21)
Mean (SD) or n (%)
Age, years 50.9 (10.5)
BMI 29.3 (5.4)
Ambulatory BP, mm Hg
Systolic 137.6 (7.7)
Diastolic 81.8 (6.3)
Baseline FMD
FMD % 4.3 (2.8)
Δ BAD, mm 0.15 (0.09)
Race
White 15 (71.4%)
Black 6 (28.6%)
Gender
Male 9 (42.8%)
Female 12 (57.2%)
Marital Status
Single 10 (47.7%)
Married 11 (52.3%)
Self-reported Health Status
Excellent, Very Good, Good 21 (100%)
Fair or Poor 0
BMI - body mass index, BP - blood pressure, FMD - flow mediated dilation,
BAD - brachial artery diameter
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shown to have effects on nitric oxide (NO) and
endothelial function, which are implicated in hyperten-
sion and CVD [27,28]. Hawthorn has been shown to
produce endothelial-dependent arterial vasodilation in
mice, rats, pigs, and humans [3,4,29,30] that is linked to
activation of endothelial NO-synthase (NOS) [3]. Studies
of different fractions of HSE have demonstrated that it
is the OPC-rich fraction that mediates hawthorn’s vaso-
dilatory effects [3,4]. Therefore, we sought to investigate
the effects of a standardized, OPC-concentrated haw-
thorn formulation on flow-mediated brachial artery dila-
tion, a measure of NO release. However, we did not
detect a dose-response effect on FMD, and no dose
appeared to have an effect significantly different than
placebo, indicating that HSE may not have a clinically
meaningful effect on NO in humans.
Formation of endogenous NO is typically mediated
by NOS through the oxidation of the amino acid L-
arginine. It is now understood that profound reduction
of NO occurs with aging so that a 40 year old adult
may only produce half as much NO as a 20 year old
[31-33]. However, strategies to increase NO production
by supplementing with L-arginine have failed to
demonstrate any clinically meaningful results in
human trials [34], leading to the conclusion that
another pathway may need to be activated to increase
NO production.
Exogenous intake of nitrate in humans is converted by
commensal bacteria to nitrite, which can then be
reduced to NO [35]. However, the reduction process
catalyzed by nitrite reductase is particularly inefficient
[36]. Zand, et al. screened over 100 botanicals and
found hawthorn to have the highest nitrate reductase
activity. They then tested a combination supplement
that was both rich in natural nitrate (beetroot) and
nitrite reductase activity (hawthorn) and found that the
supplement produced sustained in vitro NO release with
a t1/2 of about 60 minutes and rapid and sustained
human plasma NO levels (~1.4 μM) after a single dose
in vivo. Steady state human plasma nitrite concentra-
tions rose from 0.10 μM to 0.28 μM after taking the
supplement for 30 days, which was statistically signifi-
cantly greater than placebo, while plasma nitrite concen-
trations decreased in the placebo group. Finally, mildly
hypertensive participants (systolic BP 135 - 160 mm Hg,
n = 9) experienced a mean 7 mm Hg systolic and 2.7
mm Hg diastolic blood pressure reduction, although this
was not statistically significant [35].
Given what is known about the pathways of NO pro-
duction, it is possible that hawthorn alone is insufficient
to have a meaningful effect on NO and may require
addition of nitrate/nitrite to be effective in vivo. We did
not measure plasma nitrate concentration in the current
study; additionally, the mean age of our participants was
51 years and nearly all participants were older than 40
years, so the ability to produce NO was likely limited in
Table 2 Mean flow-mediated dilation, brachial artery diameter, velocity-time integral, and blood pressure by dose (N
= 21)
Placebo 1000 mg 1500 mg 2500 mg p-value1
FMD
Δ BAD, mm 0.18 (0.14) 0.16 (0.12) 0.14 (0.13) 0.17 (0.12) 0.54
FMD, % 5.3 (4.3) 5.0 (4.1) 4.3 (4.0) 4.9 (4.1) 0.59
BAD, mm
Resting 3.5 (0.7) 3.5 (0.8) 3.6 (0.8) 3.5 (0.8) 0.74
Hyperemia 3.7 (0.7) 3.6 (0.8) 3.7 (0.8) 3.7 (0.8) -
VTI, cm 85.7 (20.8) 91.3 (19.5) 82.0 (21.4) 83.9 (18.0) 0.31
Blood Pressure, mm Hg
Systolic 129.4 (8.1) 130.7 (10.7) 131.1 (13.6) 132.0 (10.0) 0.33
Diastolic 82.8 (7.3) 81.8 (7.8) 83.0 (9.1) 82.3 (7.7) 0.72
1 p-value for modified linear contrast assessing dose-response from mixed effects linear model controlling for period and baseline response. Models for FMD also
controlled for resting BAD.
All values expressed as mean (SD).
FMD - flow mediated dilation, BAD - brachial artery diameter, VTI - velocity-time integral
Table 3 Likelihood to use Hawthorn for blood pressure
control
How likely would you be to use Hawthorn for blood pressure
lowering: (N = 21)
instead of:
n (%)
in conjunction with:
n (%)
lifestyle modification1
Likely 14 (66.6) 19 (90.5)
Unsure 4 (19.0) 0
Unlikely 3 (14.4) 2 (9.5)
antihypertensive medication
Likely 18 (85.7) 12 (57.2)
Unsure 2 (9.5) 5 (23.8)
Unlikely 1 (4.8) 4 (19.0)
1Lifestyle modification defined as dietary and/or exercise modifications.
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our study population. Therefore, our study results may
reflect a poor native ability to produce NO.
Studies of hawthorn to lower BP in humans suggest
benefits, although only three small randomized, pla-
cebo-controlled trials have been performed [9-11].
Asgary, et al. treated mildly hypertensive adults for 16
weeks and observed mean systolic and diastolic BP
reductions of 13 mm Hg and 8 mm Hg respectively.
Walker, et al. studied both untreated mildly hyperten-
sive patients and treated hypertensive diabetic patients
for 10-16 weeks and observed systolic BP reductions of
3.6-10 mm Hg and diastolic BP reductions of 2.6-7
mm Hg. Other studies of the effect of hawthorn on
heart failure also suggest that it may have a BP lower-
ing effect, although BP was a secondary outcome in
each of those studies [19,20]. All hawthorn studies to
lower BP have had a minimum 10 week intervention
period and the German Commission E recommends a
minimum of 6 weeks [37]. Even if hawthorn has no
effect on NO, it is still worthwhile to investigate the
effects of hawthorn on blood pressure given the results
of these prior trials.
Limitations
Several limitations of this study should be considered.
Although we measured adherence by self-report, poor
adherence could have masked any effect of hawthorn,
and we did not include a pharmacologic adherence
assessment. However, no individual participants exhib-
ited a dose-response effect, and it would be very unlikely
that all participants were uniformly poorly adherent.
Pharmacokinetic parameters of hawthorn constituents
are poorly described for humans. Reports in rodents
demonstrate poor oral absorption and bioavailability for
some constituents of hawthorn [21]. Poor absorption of
the HSE pills could confound our results, but would not
contradict preclinical in vitro and ex vivo findings. How-
ever, similar doses of HSE have been used for trials in
patients with HF that have shown beneficial effects, sug-
gesting there is sufficient oral bioavailability of HSE to
demonstrate physiologic effects. It is possible that twice
daily dosing of HSE for 4 days is insufficient to have an
effect on NO production. However, most mechanisms
to increase NO production in response to shear stress,
such as that produced during FMD, take minutes to
hours to occur (eg. calcium ion flux, eNOS activation,
eNOS gene transcription) [23].
Little is known about differences among HSE formula-
tions so our results may not be generalizable to other
hawthorn formulations. The extract for this trial was a
whole leaf and flower formulation with sufficient plant
material to provide OPC at high concentrations. Other
extraction techniques may favor a different mix of con-
stituents (ie. hydrophilic vs hydrophobic extraction
processes), as would doping a low OPC extract with
additional OPC-rich fraction to obtain high OPC
concentrations.
Conclusion
We found no evidence that flow mediated dilation, an
indirect measure of NO, is altered by multidose admin-
istration of hawthorn standardized extract. If there is a
blood pressure lowering effect of hawthorn, it is likely
to occur by mechanisms other than NO-mediated
vasodilation.
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